Consolidated Research: 2018 Summary Expectations for TD Ameritrade Holding, Supernus Pharmaceuticals, Akcea Therapeutics, Dell Technologies, iRobot, and Pegasystems — Fundamental Analysis, Key Performance Indications

Loading...
Loading...

NEW YORK, Dec. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of TD Ameritrade Holding Corporation AMTD, Supernus Pharmaceuticals, Inc. SUPN, Akcea Therapeutics, Inc. AKCA, Dell Technologies Inc. DVMT, iRobot Corporation IRBT, and Pegasystems Inc. PEGA, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

AMTD DOWNLOAD: http://MarketSourceResearch.com/register/?so=AMTD
SUPN DOWNLOAD: http://MarketSourceResearch.com/register/?so=SUPN
AKCA DOWNLOAD: http://MarketSourceResearch.com/register/?so=AKCA
DVMT DOWNLOAD: http://MarketSourceResearch.com/register/?so=DVMT
IRBT DOWNLOAD: http://MarketSourceResearch.com/register/?so=IRBT
PEGA DOWNLOAD: http://MarketSourceResearch.com/register/?so=PEGA

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine TD Ameritrade Holding Corporation AMTD, Supernus Pharmaceuticals, Inc. SUPN, Akcea Therapeutics, Inc. AKCA, Dell Technologies Inc. DVMT, iRobot Corporation IRBT, and Pegasystems Inc. PEGA on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed December 3rd, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

Loading...
Loading...

TD AMERITRADE HOLDING CORPORATION (AMTD) REPORT OVERVIEW

TD Ameritrade Holding's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, TD Ameritrade Holding reported revenue of $1,398.00MM vs $982.00MM (up 42.36%) and analysts estimated basic earnings per share $0.81 vs $0.39 (up 107.69%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, TD Ameritrade Holding reported revenue of $5,452.00MM vs $3,676.00MM (up 48.31%) and analysts estimated basic earnings per share $2.60 vs $1.65 (up 57.58%). Analysts expect earnings to be released on January 28th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.80. The estimated EPS forecast for the next fiscal year is $4.42 and is expected to report on October 28th, 2019.

To read the full TD Ameritrade Holding Corporation (AMTD) report, download it here: http://MarketSourceResearch.com/register/?so=AMTD

-----------------------------------------

SUPERNUS PHARMACEUTICALS, INC. (SUPN) REPORT OVERVIEW

Supernus Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Supernus Pharmaceuticals reported revenue of $103.00MM vs $80.40MM (up 28.11%) and analysts estimated basic earnings per share $0.54 vs $0.31 (up 74.19%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Supernus Pharmaceuticals reported revenue of $302.24MM vs $215.00MM (up 40.57%) and analysts estimated basic earnings per share $1.13 vs $1.84 (down 38.59%). Analysts expect earnings to be released on February 26th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $2.38 and is expected to report on February 26th, 2019.

To read the full Supernus Pharmaceuticals, Inc. (SUPN) report, download it here: http://MarketSourceResearch.com/register/?so=SUPN

-----------------------------------------

AKCEA THERAPEUTICS, INC. (AKCA) REPORT OVERVIEW

Akcea Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Akcea Therapeutics reported revenue of $19.24MM vs $9.91MM (up 94.24%) and analysts estimated basic earnings per share -$0.97 vs -$0.48. Analysts expect earnings to be released on February 25th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.26. The estimated EPS forecast for the next fiscal year is $0.92 and is expected to report on February 25th, 2019.

To read the full Akcea Therapeutics, Inc. (AKCA) report, download it here: http://MarketSourceResearch.com/register/?so=AKCA

-----------------------------------------

DELL TECHNOLOGIES INC. (DVMT) REPORT OVERVIEW

Dell Technologies' Recent Financial Performance

For the three months ended July 31st, 2018 vs July 31st, 2017, Dell Technologies reported revenue of $22,942.00MM vs $19,521.00MM (up 17.52%) and basic earnings per share -$0.65 vs -$0.95. For the twelve months ended January 31st, 2018 vs January 31st, 2017, Dell Technologies reported revenue of $78,660.00MM vs $61,642.00MM (up 27.61%) and analysts estimated basic earnings per share -$5.67 vs -$2.78. Analysts expect earnings to be released on March 14th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was $2.39. The estimated EPS forecast for the next fiscal year is $6.45 and is expected to report on March 14th, 2019.

To read the full Dell Technologies Inc. (DVMT) report, download it here: http://MarketSourceResearch.com/register/?so=DVMT

-----------------------------------------

IROBOT CORPORATION (IRBT) REPORT OVERVIEW

iRobot's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, iRobot reported revenue of $264.53MM vs $205.40MM (up 28.79%) and analysts estimated basic earnings per share $1.16 vs $0.80 (up 45.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, iRobot reported revenue of $883.91MM vs $660.60MM (up 33.80%) and analysts estimated basic earnings per share $1.85 vs $1.51 (up 22.52%). Analysts expect earnings to be released on February 6th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.54. The estimated EPS forecast for the next fiscal year is $2.88 and is expected to report on February 6th, 2019.

To read the full iRobot Corporation (IRBT) report, download it here: http://MarketSourceResearch.com/register/?so=IRBT

-----------------------------------------

PEGASYSTEMS INC. (PEGA) REPORT OVERVIEW

Pegasystems' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Pegasystems reported revenue of $203.26MM vs $190.96MM (up 6.44%) and analysts estimated basic earnings per share -$0.10 vs $0.01. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Pegasystems reported revenue of $840.58MM vs $750.27MM (up 12.04%) and analysts estimated basic earnings per share $0.43 vs $0.35 (up 22.86%). Analysts expect earnings to be released on February 25th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.11. The estimated EPS forecast for the next fiscal year is $0.11 and is expected to report on February 25th, 2019.

To read the full Pegasystems Inc. (PEGA) report, download it here: http://MarketSourceResearch.com/register/?so=PEGA

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at compliance@MarketSourceResearch.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Hugo Moreau, Media Department
Office: +1 (704) 343-6361
E-mail: media@MarketSourceResearch.com

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@MarketSourceResearch.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...